Research Analysts Issue Forecasts for BPMC Q1 Earnings

Blueprint Medicines Co. (NASDAQ:BPMC) – Research analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for Blueprint Medicines in a note issued to investors on Thursday, February 13th. Leerink Partnrs analyst A. Berens forecasts that the biotechnology company will post earnings of ($0.77) per share for the quarter. The consensus estimate for Blueprint Medicines’ current full-year earnings is ($3.63) per share. Leerink Partnrs also issued estimates for Blueprint Medicines’ Q2 2025 earnings at ($0.61) EPS, Q3 2025 earnings at ($0.49) EPS and Q4 2025 earnings at ($0.37) EPS.

Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%.

BPMC has been the topic of several other research reports. HC Wainwright reiterated a “buy” rating and issued a $135.00 price target on shares of Blueprint Medicines in a report on Friday, February 14th. JMP Securities reiterated a “market outperform” rating and issued a $125.00 price target on shares of Blueprint Medicines in a report on Friday, February 14th. Stephens reiterated an “overweight” rating and issued a $140.00 price target on shares of Blueprint Medicines in a report on Thursday, January 2nd. Wells Fargo & Company cut their price target on shares of Blueprint Medicines from $153.00 to $151.00 and set an “overweight” rating on the stock in a report on Thursday, October 31st. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $133.00 price target on shares of Blueprint Medicines in a report on Thursday, February 13th. Two research analysts have rated the stock with a sell rating, six have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $123.83.

Blueprint Medicines Stock Performance

BPMC opened at $92.48 on Monday. Blueprint Medicines has a 52-week low of $80.42 and a 52-week high of $121.90. The company has a quick ratio of 3.27, a current ratio of 3.32 and a debt-to-equity ratio of 1.09. The company has a market cap of $5.88 billion, a P/E ratio of -43.83 and a beta of 0.62. The firm’s 50-day moving average price is $99.54 and its 200-day moving average price is $94.40.

Insider Activity

In other news, Director Jeffrey W. Albers sold 15,000 shares of the stock in a transaction that occurred on Thursday, December 19th. The stock was sold at an average price of $89.77, for a total transaction of $1,346,550.00. Following the transaction, the director now owns 157,557 shares in the company, valued at $14,143,891.89. This trade represents a 8.69 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Kate Haviland sold 2,353 shares of the stock in a transaction on Friday, November 29th. The shares were sold at an average price of $96.60, for a total value of $227,299.80. Following the completion of the transaction, the chief executive officer now directly owns 150,824 shares of the company’s stock, valued at approximately $14,569,598.40. This represents a 1.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 49,851 shares of company stock worth $4,984,696 in the last quarter. Corporate insiders own 4.21% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in BPMC. CWM LLC increased its stake in shares of Blueprint Medicines by 69.2% in the 3rd quarter. CWM LLC now owns 1,870 shares of the biotechnology company’s stock worth $173,000 after acquiring an additional 765 shares during the last quarter. Creative Planning increased its position in shares of Blueprint Medicines by 6.8% during the 3rd quarter. Creative Planning now owns 13,194 shares of the biotechnology company’s stock worth $1,220,000 after purchasing an additional 843 shares during the last quarter. Allspring Global Investments Holdings LLC increased its position in shares of Blueprint Medicines by 40.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 3,206 shares of the biotechnology company’s stock worth $297,000 after purchasing an additional 927 shares during the last quarter. Values First Advisors Inc. acquired a new stake in shares of Blueprint Medicines during the 3rd quarter worth about $122,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in shares of Blueprint Medicines by 22.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,291 shares of the biotechnology company’s stock worth $212,000 after purchasing an additional 422 shares during the last quarter.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.